|Cat. No. :
|Product Overview :
||Recombinant human soluble Vascular Endothelial Growth Factor Receptor-3 (sVEGFR-3/FLT-4) was fused with a carboxy -terminal 6X histidine-tag. The recombinant mature sVEGFR-3/FLT-4 is a glycosylated monomeric protein. The sVEGFR-3/FLT -4 monomers have a mass of approximately 120 kDa. The soluble receptor protein consists of all 7 extracellular domains (Met1-Glu774). It is produced inInsect cells.
||All three VEGF receptors belong to the class III subfamily of receptor tyrosine kinases (RTKs) characterised by the seven immunoglobulin-like loops in the extracellular domain. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. They play key roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The FLT -4 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 23 aa residue signal peptide. Mature VEGFR-3/FLT-4 is composed of a 751 aa residue extracellular domain, a 22 aa transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF family members VEGF-C and VEGF-D have been shown to bind and activate VEGFR-3/FLT-4.
||> 90%, by SDS-PAGE and visualised by silver stain.
||The lyophilised sVEGFR-3/FLT-4 is soluble in water and most aqueous buffers. The lyophilised sVEGFR-3/FLT-4 should be reconstituted in PBS or medium to a concentration not lower than 100 µg/ml.
|Specific Activity :
||Measured by its ability to bind recombinant rat VEGF-C in a functional solid phase binding assay. Immobilised recombinant human sVEGFR-3/FLT-4 at 5 µg/ml can bind recombinant rat VEGF-C in a linear range of 8-500 ng/ml.
|Endotoxin level :
||< 0.1 ng per mg of sVEGFR-3.
||Lyophilised samples are stable for greater than six months at -20°C to -70°C. Reconstituted sVEGFR-3/FLT -4 should be stored in working aliquots at -20°C. Avoid repeated freeze-thaw cycles.